Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001658809 | SCV001873935 | uncertain significance | not provided | 2021-07-23 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (Lek et al., 2016); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002488446 | SCV002789103 | uncertain significance | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome; Polysyndactyly 4; Polydactyly, postaxial, type A1 | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003771819 | SCV004570231 | uncertain significance | Greig cephalopolysyndactyly syndrome; Pallister-Hall syndrome | 2023-03-18 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with GLI3-related conditions. ClinVar contains an entry for this variant (Variation ID: 1254627). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt GLI3 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with arginine, which is basic and polar, at codon 1052 of the GLI3 protein (p.Pro1052Arg). |
Ambry Genetics | RCV004631729 | SCV005123609 | uncertain significance | Inborn genetic diseases | 2024-03-26 | criteria provided, single submitter | clinical testing | The c.3155C>G (p.P1052R) alteration is located in exon 15 (coding exon 14) of the GLI3 gene. This alteration results from a C to G substitution at nucleotide position 3155, causing the proline (P) at amino acid position 1052 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |